Prostate Cancer

African American Men Face Higher Risk of Aggressive Prostate Cancer, but Not Necessarily Death

November 26th 2020, 6:30pm


Multiple studies have suggested African American men tend to have more aggressive forms of prostate cancer, but a new study suggests that may not translate to a higher risk of death.

Genetic Signature Could Predict Prostate Cancer Metastasis

November 24th 2020, 3:00pm


The discovery of a genetic signature that correlates with metastasis in prostate cancer could make it much easier for physicians and patients to choose treatment strategies.

Commentary Examines What Is Known About BRCA1 Mutations Compared With BRCA2 in Prostate Cancer

November 21st 2020, 4:10pm


Authors in the Journal of Clinical Oncology discuss hypotheses on the differences in mutations and implications for treatment with PARP inhibitors.

Is a Brighter Future Possible for PARP Inhibitor Use in Prostate Cancer?

November 20th 2020, 9:48pm


Mounting evidence is supporting the use of poly ADP-ribose polymerase (PARP) inhibitors in prostate cancer, according to a new study.

Olaparib Cuts Risk of Death 31% in BRCA 1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer

September 21st 2020, 2:16pm


Having biomarker-driven solutions in prostate cancer is important, because they have been lacking.

FDA Approves Olaparib for HRR Gene–Mutated Metastatic Castration-Resistant Prostate Cancer

May 20th 2020, 11:48pm


The therapy is for patients with deleterious or suspected deleterious germline somatic homologous recombination repair (HRR) gene–mutated cancer or for those whose cancer has progressed after prior treatment with enzalutamide or abiraterone.

NCCN Prostate Cancer Update Emphasizes Germline Testing

March 22nd 2019, 10:38pm


Germline testing at diagnosis, along with tumor testing, have the potential to identify candidates for investigational poly (ADP-ribose) polymerase (PARP) inhibitors, and updated guidelines call for their expanded use.

USPSTF Recommends Patient Choice for Prostate Cancer Screening

May 11th 2018, 12:41am


The US Preventive Services Task Force (USPSTF) recommends that men aged 55 to 69 make their own decision on whether or not to be screened periodically for prostate cancer after they have had a conversation with their physician on potential benefits and harms.